Table 2 Comparison of cost and clinical outcome measures between groups that were included in the economic evaluation

$AUD lost productivity (total over 12 months)

$-6081 ($19, 627),

$-958 ($20,364)

$-5123 ($-10,174, $-72)

$AUD increase in medication use (total over 12 months)

$81 ($170)

$166 ($293)

$-85 ($-238, $68)

$AUD absolute imaging use

$52 ($191)

$66 ($169)

$-14 ($-125, $97)

$AUD absolute non-trial medical & therapies use

$137 ($232)

$170 ($285)

$-53 ($-105, $-0)

$AUD absolute trial medical & therapies use

$993 ($217)

$516 ($71)

$477 ($447, $508)

$AUD total cost (primary analysis)

$-4822 ($19,667)

$-40 ($20,278)

$-4781 ($-9748, $186)

$AUD total cost (sensitivity analysis)

$-4822 ($19,667)

$-557 ($20,277)

$-4265 ($-9221, $691)

Patient Global Impression of Change

8 Very much improved

2 Very much improved

15 Much improved

7 Much improved

10 Minimally improved

3 Minimally improved

5 No change

21 No change

0 Minimally worse

10 Minimally worse

0 Much worse

1 Much worse

0 Very much worse

1 Very much worse

n (%) very or much improved on Patient Global Impression of Change (primary analysis)

23 (61%)

9 (20%)

0.41 (0.27, 0.54)

n (%) very or much or minimally improved on Patient Global Impression of Change (sensitivity analysis)

33 (87%)

12 (26%)

0.60 (0.46, 0.74)